176 related articles for article (PubMed ID: 28515147)
1. Increased T-cell Infiltration Elicited by
Loveridge CJ; Mui EJ; Patel R; Tan EH; Ahmad I; Welsh M; Galbraith J; Hedley A; Nixon C; Blyth K; Sansom O; Leung HY
Cancer Res; 2017 Jun; 77(12):3158-3168. PubMed ID: 28515147
[TBL] [Abstract][Full Text] [Related]
2. Concomitant loss of EAF2/U19 and Pten synergistically promotes prostate carcinogenesis in the mouse model.
Ai J; Pascal LE; O'Malley KJ; Dar JA; Isharwal S; Qiao Z; Ren B; Rigatti LH; Dhir R; Xiao W; Nelson JB; Wang Z
Oncogene; 2014 May; 33(18):2286-94. PubMed ID: 23708662
[TBL] [Abstract][Full Text] [Related]
3. PTEN-deficient prostate cancer is associated with an immunosuppressive tumor microenvironment mediated by increased expression of IDO1 and infiltrating FoxP3+ T regulatory cells.
Vidotto T; Saggioro FP; Jamaspishvili T; Chesca DL; Picanço de Albuquerque CG; Reis RB; Graham CH; Berman DM; Siemens DR; Squire JA; Koti M
Prostate; 2019 Jun; 79(9):969-979. PubMed ID: 30999388
[TBL] [Abstract][Full Text] [Related]
4. Tumor heterogeneity, aggressiveness, and immune cell composition in a novel syngeneic PSA-targeted Pten knockout mouse prostate cancer (MuCaP) model.
van Duijn PW; Marques RB; Ziel-van der Made ACJ; van Zoggel HJAA; Aghai A; Berrevoets C; Debets R; Jenster G; Trapman J; van Weerden WM
Prostate; 2018 Sep; 78(13):1013-1023. PubMed ID: 30133757
[TBL] [Abstract][Full Text] [Related]
5. Proteomic and transcriptomic profiling of Pten gene-knockout mouse model of prostate cancer.
Zhang J; Kim S; Li L; Kemp CJ; Jiang C; Lü J
Prostate; 2020 May; 80(7):588-605. PubMed ID: 32162714
[TBL] [Abstract][Full Text] [Related]
6. Potentiation of inflammatory CXCL8 signalling sustains cell survival in PTEN-deficient prostate carcinoma.
Maxwell PJ; Coulter J; Walker SM; McKechnie M; Neisen J; McCabe N; Kennedy RD; Salto-Tellez M; Albanese C; Waugh DJ
Eur Urol; 2013 Aug; 64(2):177-88. PubMed ID: 22939387
[TBL] [Abstract][Full Text] [Related]
7. In situ vaccination combined with androgen ablation and regulatory T-cell depletion reduces castration-resistant tumor burden in prostate-specific pten knockout mice.
Akins EJ; Moore ML; Tang S; Willingham MC; Tooze JA; Dubey P
Cancer Res; 2010 May; 70(9):3473-82. PubMed ID: 20406970
[TBL] [Abstract][Full Text] [Related]
8. Timp3 loss accelerates tumour invasion and increases prostate inflammation in a mouse model of prostate cancer.
Adissu HA; McKerlie C; Di Grappa M; Waterhouse P; Xu Q; Fang H; Khokha R; Wood GA
Prostate; 2015 Dec; 75(16):1831-43. PubMed ID: 26332574
[TBL] [Abstract][Full Text] [Related]
9. Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by intermittent anti-PI3Kα/β/δ treatment.
Qi Z; Xu Z; Zhang L; Zou Y; Li J; Yan W; Li C; Liu N; Wu H
Nat Commun; 2022 Jan; 13(1):182. PubMed ID: 35013322
[TBL] [Abstract][Full Text] [Related]
10. Chromatin Regulator CHD1 Remodels the Immunosuppressive Tumor Microenvironment in PTEN-Deficient Prostate Cancer.
Zhao D; Cai L; Lu X; Liang X; Li J; Chen P; Ittmann M; Shang X; Jiang S; Li H; Meng C; Flores I; Song JH; Horner JW; Lan Z; Wu CJ; Li J; Chang Q; Chen KC; Wang G; Deng P; Spring DJ; Wang YA; DePinho RA
Cancer Discov; 2020 Sep; 10(9):1374-1387. PubMed ID: 32385075
[TBL] [Abstract][Full Text] [Related]
11. Multi-faceted immunomodulatory and tissue-tropic clinical bacterial isolate potentiates prostate cancer immunotherapy.
Anker JF; Naseem AF; Mok H; Schaeffer AJ; Abdulkadir SA; Thumbikat P
Nat Commun; 2018 Apr; 9(1):1591. PubMed ID: 29686284
[TBL] [Abstract][Full Text] [Related]
12. The transcription factor FOXF1 promotes prostate cancer by stimulating the mitogen-activated protein kinase ERK5.
Fulford L; Milewski D; Ustiyan V; Ravishankar N; Cai Y; Le T; Masineni S; Kasper S; Aronow B; Kalinichenko VV; Kalin TV
Sci Signal; 2016 May; 9(427):ra48. PubMed ID: 27165781
[TBL] [Abstract][Full Text] [Related]
13. Loss of Nkx3.1 leads to the activation of discrete downstream target genes during prostate tumorigenesis.
Song H; Zhang B; Watson MA; Humphrey PA; Lim H; Milbrandt J
Oncogene; 2009 Sep; 28(37):3307-19. PubMed ID: 19597465
[TBL] [Abstract][Full Text] [Related]
14. CD4
Liu S; Liu F; Zhang B; Yan P; Rowan BG; Abdel-Mageed AB; Steele C; Jazwinski SM; Moroz K; Norton EB; Wang A; Myers L; Sartor O; Zhang Q
Prostate; 2020 Jul; 80(10):764-776. PubMed ID: 32356608
[TBL] [Abstract][Full Text] [Related]
15. Slow disease progression in a C57BL/6 pten-deficient mouse model of prostate cancer.
Svensson RU; Haverkamp JM; Thedens DR; Cohen MB; Ratliff TL; Henry MD
Am J Pathol; 2011 Jul; 179(1):502-12. PubMed ID: 21703427
[TBL] [Abstract][Full Text] [Related]
16. BRF1 accelerates prostate tumourigenesis and perturbs immune infiltration.
Loveridge CJ; Slater S; Campbell KJ; Nam NA; Knight J; Ahmad I; Hedley A; Lilla S; Repiscak P; Patel R; Salji M; Fleming J; Mitchell L; Nixon C; Strathdee D; Neilson M; Ntala C; Bryson S; Zanivan S; Edwards J; Robson CN; Goodyear CS; Blyth K; Leung HY
Oncogene; 2020 Feb; 39(8):1797-1806. PubMed ID: 31740786
[TBL] [Abstract][Full Text] [Related]
17. Interaction of the Androgen Receptor, ETV1, and PTEN Pathways in Mouse Prostate Varies with Pathological Stage and Predicts Cancer Progression.
Higgins J; Brogley M; Palanisamy N; Mehra R; Ittmann MM; Li JZ; Tomlins SA; Robins DM
Horm Cancer; 2015 Jun; 6(2-3):67-86. PubMed ID: 25631336
[TBL] [Abstract][Full Text] [Related]
18. Infiltrating CD4+ T cells attenuate chemotherapy sensitivity in prostate cancer via CCL5 signaling.
Xiang P; Jin S; Yang Y; Sheng J; He Q; Song Y; Yu W; Hu S; Jin J
Prostate; 2019 Jun; 79(9):1018-1031. PubMed ID: 31018021
[TBL] [Abstract][Full Text] [Related]
19. Diverse genetic-driven immune landscapes dictate tumor progression through distinct mechanisms.
Bezzi M; Seitzer N; Ishikawa T; Reschke M; Chen M; Wang G; Mitchell C; Ng C; Katon J; Lunardi A; Signoretti S; Clohessy JG; Zhang J; Pandolfi PP
Nat Med; 2018 Feb; 24(2):165-175. PubMed ID: 29309058
[TBL] [Abstract][Full Text] [Related]
20. Pten null prostate epithelium promotes localized myeloid-derived suppressor cell expansion and immune suppression during tumor initiation and progression.
Garcia AJ; Ruscetti M; Arenzana TL; Tran LM; Bianci-Frias D; Sybert E; Priceman SJ; Wu L; Nelson PS; Smale ST; Wu H
Mol Cell Biol; 2014 Jun; 34(11):2017-28. PubMed ID: 24662052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
